Literature DB >> 12669456

Recent advances in the development of immunostimulatory oligonucleotides.

Eugen Uhlmann1, Joerg Vollmer.   

Abstract

Some immune cells recognize distinct molecular structures present in pathogens through specific pattern recognition receptors that are able to distinguish prokaryotic DNA from vertebrate DNA. The detection of invading microbial DNA is based on the recognition of unmethylated deoxycytidyl-deoxyguanosin dinucleotide (CpG) motifs. Synthetic oligonucleotides (ODNs) containing these CpG motifs are able to activate both innate and acquired immune responses through a signaling pathway involving Toll-like receptor 9 (TLR9). Depending on the sequence, length, as well as number and positions of CpG motifs in an ODN, distinct immunostimulatory profiles can be observed. These immunostimulatory profiles can be further modified and fine-tuned by appropriate chemical modifications, leading to preclinical and clinical development of CpG ODNs in cancer, allergy, asthma and infectious diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12669456

Source DB:  PubMed          Journal:  Curr Opin Drug Discov Devel        ISSN: 1367-6733


  14 in total

Review 1.  DNA-Based Biomaterials for Immunoengineering.

Authors:  Midori Maeda; Taisuke Kojima; Yang Song; Shuichi Takayama
Journal:  Adv Healthc Mater       Date:  2018-12-05       Impact factor: 9.933

2.  Immunopharmacology of CpG oligodeoxynucleotides and ribavirin.

Authors:  Jörg Vollmer; Robert Rankin; Hanna Hartmann; Marion Jurk; Ulrike Samulowitz; Tanja Wader; Andrea Janosch; Christian Schetter; Arthur M Krieg
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

3.  Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation.

Authors:  Jörg Vollmer; Risini D Weeratna; Marion Jurk; Ulrike Samulowitz; Michael J McCluskie; Paul Payette; Heather L Davis; Christian Schetter; Arthur M Krieg
Journal:  Immunology       Date:  2004-10       Impact factor: 7.397

4.  Folate-immunoglobulin G as an anticancer therapeutic antibody.

Authors:  Hong Li; Yanhui Lu; Longzhu Piao; Jun Wu; Xiaojuan Yang; Sri Vidya Kondadasula; William E Carson; Robert J Lee
Journal:  Bioconjug Chem       Date:  2010-05-19       Impact factor: 4.774

5.  Toll-like receptor (TLR) 3 immune modulation by unformulated small interfering RNA or DNA and the role of CD14 (in TLR-mediated effects).

Authors:  Cordula Weber; Christian Müller; Anja Podszuweit; Carmen Montino; Jörg Vollmer; Alexandra Forsbach
Journal:  Immunology       Date:  2012-05       Impact factor: 7.397

6.  Enhanced bleaching treatment: opportunities for immune-assisted melanocyte suicide in vitiligo.

Authors:  Kirsten C Webb; Jonathan M Eby; Vidhya Hariharan; Claudia Hernandez; Rosalie M Luiten; I Caroline Le Poole
Journal:  Exp Dermatol       Date:  2014-07-10       Impact factor: 3.960

7.  Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy.

Authors:  Darya Alizadeh; Leying Zhang; Christine E Brown; Omar Farrukh; Michael C Jensen; Behnam Badie
Journal:  Clin Cancer Res       Date:  2010-06-22       Impact factor: 12.531

8.  Positive T cell co-stimulation by TLR7/8 ligands is dependent on the cellular environment.

Authors:  Denise Richardt-Pargmann; Miriam Wechsler; Arthur M Krieg; Jörg Vollmer; Marion Jurk
Journal:  Immunobiology       Date:  2010-04-09       Impact factor: 3.144

9.  Immunomodulatory properties of subcellular fractions of a G+ bacterium, Bacillus firmus.

Authors:  Dana Cechova; Michaela Novakova; Karel Mikulik; Olga Novotna; Jaroslav Julak; Peter Zanvit; Ludmila Prokesova
Journal:  Folia Microbiol (Praha)       Date:  2012-08-09       Impact factor: 2.099

10.  CpG oligodeoxynucleotides block human immunodeficiency virus type 1 replication in human lymphoid tissue infected ex vivo.

Authors:  Erika Schlaepfer; Annette Audigé; Barbara von Beust; Vania Manolova; Markus Weber; Helene Joller; Martin F Bachmann; Thomas M Kundig; Roberto F Speck
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.